Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Featured
Page 86
Featured
Featured posts
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
BridgeBio’s BEYONTTRA approved by European Commission to treat ATTR-CM
UK unveils funding for AI companies to transform cancer care and spark new drug breakthroughs
Caris Life Sciences enters into broad precision medicine partnership to advance...
9th March 2023
Noema Pharma raises $112m in Series B financing round
8th March 2023
Confo Therapeutics signs global licensing agreement with Lilly for peripheral pain...
8th March 2023
Bristol Myers Squibb receives European Commission approval of Reblozyl for anemia...
8th March 2023
Biotech firm with product to help heal eye injuries raises further...
8th March 2023
Ipsen completes acquisition of Albireo
7th March 2023
86% of pharma and biotech companies plan to invest in ‘digitally...
7th March 2023
Tevard Biosciences and Vertex to develop novel tRNA-based therapies for Duchenne...
3rd March 2023
Reata Pharmaceuticals’ SKYCLARYS approved by FDA for Friedreich’s ataxia
3rd March 2023
Kevzara approved by U.S. FDA for patients with polymyalgia rheumatica
2nd March 2023
1
...
85
86
87
...
146
Page 86 of 146
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...